Compounded vs. Branded Combination Estrogen-Progestogen Patches: What Women Need to Know About CombiPatch and Climara Pro

Why the Compounded-vs-Branded Question Matters for Women With a Uterus

For women who still have their uterus, estrogen-alone hormone therapy is not safe long-term. Unopposed estrogen stimulates the endometrium and raises the risk of endometrial hyperplasia and cancer. Adding a progestogen counters that risk, and a combination patch does the work in a single adhesive system.

The choice between a branded patch, CombiPatch or Climara Pro, and a compounded combination patch is not simply about cost or convenience. It touches on endometrial safety, hormonal consistency, pharmacokinetic reliability, and FDA oversight. This article lays out the clinical evidence and practical differences so you can have a more specific conversation with your prescriber.

The Two Branded Patches: How They Differ

CombiPatch delivers 0.05 mg estradiol plus 0.14 mg norethindrone acetate (NETA) per day. You apply a new patch twice weekly. FDA prescribing information for CombiPatch documents the approved dose matrix and release kinetics.

Climara Pro delivers 0.045 mg estradiol plus 0.015 mg levonorgestrel (LNG) per day from a once-weekly patch. The progestogen differs: levonorgestrel is a 19-nortestosterone derivative with higher androgenic activity than NETA, which can matter for women sensitive to androgenic side effects such as acne or mood changes.

Both patches are indicated for the treatment of moderate-to-severe vasomotor symptoms of menopause in women with a uterus. Neither is indicated for osteoporosis prevention as a primary goal, though estradiol does have skeletal benefits.

What "Compounded" Means in This Context

A compounded combination patch is mixed and assembled by a licensed compounding pharmacy. No FDA-approved standard exists for a compounded transdermal estradiol-progestogen combination patch. The FDA's position on compounded bioidentical hormones is that compounded preparations lack the safety and efficacy evidence that approved products carry, and that this applies to combination products as much as single-hormone ones.

Compounded pharmacies can formulate with different progestogens (including progesterone, estriol combinations, or others) and at custom doses. That flexibility is sometimes cited as a benefit. The tradeoff is the absence of standardized release-rate data, potency verification at the batch level, and long-term endometrial safety data for those specific formulations.

Clinical Trial Evidence for Continuous Combined Transdermal HRT

The trial most directly relevant to branded combination patches is the continuous combined transdermal HRT study by Rozenberg and colleagues, which evaluated symptom control and endometrial protection with continuous combined transdermal estrogen-progestogen. The study found no cases of endometrial hyperplasia at 12 months in the continuous combined arm, compared to significant rates in women receiving unopposed transdermal estradiol. Vasomotor symptoms were controlled effectively.

This trial matters because it is the type of endometrial safety data that the FDA required to approve combination patches. No equivalent endometrial biopsy dataset exists for compounded combination transdermal products. That is not a minor gap. It is the central clinical question for any woman with a uterus who is considering this therapy.

What the Trial Population Looked Like

The women enrolled were primarily postmenopausal, with intact uteri and moderate-to-severe vasomotor symptoms. The mean age was in the early-to-mid 50s. Women in early perimenopause, or those with irregular cycles but not yet amenorrheic for 12 months, were not the studied population. If you are perimenopausal, extrapolating this data to your situation requires care.

Symptom Control Outcomes

Vasomotor symptom frequency and severity fell substantially in the continuous combined transdermal group. The Menopause Society (formerly NAMS) position statement on hormone therapy affirms that transdermal estradiol at doses approximating those in branded combination patches is effective for vasomotor symptoms and carries a lower venous thromboembolism (VTE) risk than oral preparations, because transdermal delivery avoids first-pass hepatic metabolism.

Endometrial Protection: The Non-Negotiable

An analysis published in Fertility and Sterility confirmed that continuous combined progestogen exposure, as opposed to sequential progestogen, eliminates the withdrawal bleed for most postmenopausal women and maintains endometrial suppression. Amenorrhea rates with CombiPatch reach approximately 70-80% by month 6 in postmenopausal women per FDA-reviewed clinical data. Compounded patches carry no such independently audited figure.

Pharmacokinetics: Why Transdermal Delivery Differs From Oral

Transdermal estradiol bypasses the liver entirely. This means you do not get the hepatic first-pass effect that oral estrogens produce. That matters for several reasons:

• VTE risk: Oral estrogens increase hepatic synthesis of clotting factors. Transdermal estradiol does not show the same prothrombotic signal. A large observational study in the BMJ found that transdermal estradiol was not associated with increased VTE risk, unlike oral preparations.
• Triglycerides: Oral estrogen can raise triglycerides; transdermal does not, which matters for women with hypertriglyceridemia or metabolic syndrome.
• Sex hormone-binding globulin (SHBG): Oral estrogen raises SHBG, which binds free testosterone and can lower libido. Transdermal estradiol raises SHBG minimally.

Progestogen Pharmacokinetics in the Patch

NETA (CombiPatch) and LNG (Climara Pro) are both absorbed transdermally, but their systemic profiles differ from oral administration of the same progestogens. Transdermal NETA does not undergo the extensive first-pass metabolism that oral NETA does. Serum concentrations are lower and steadier. Published pharmacokinetic data from the continuous combined transdermal trial confirmed stable serum estradiol and progestogen levels across the patch wear period, without the peaks and troughs associated with oral dosing.

Compounded transdermal combinations have not published equivalent PK profiles for their specific formulations. A compounding pharmacy can target a dose, but without bioavailability studies in women, the actual systemic exposure is unknown.

Female-Specific PK Considerations

Body composition, skin thickness, and blood flow to the application site all affect transdermal absorption. Postmenopausal women tend to have lower subcutaneous blood flow than younger women, which can affect delivery rate. Obesity alters adipose tissue distribution and drug sequestration. Neither branded nor compounded patches have dose-adjustment labeling based on body mass index, but clinicians sometimes increase patch dose or frequency empirically in women with BMI <27 who report poor symptom control and in those with higher BMI who may have altered absorption.

Who This Is Right For and Who Should Look Elsewhere

The following framework is designed to guide the conversation with your clinician, organized by life stage and clinical situation.

Postmenopausal Women (12+ Months Without a Period)

This is the population with the strongest evidence base. If you are postmenopausal, have a uterus, experience moderate-to-severe hot flashes or night sweats, and want a once-or-twice-weekly patch without daily pills, a branded combination patch is a well-supported first choice. CombiPatch or Climara Pro cover both symptom control and endometrial protection in a single system.

A compounded combination patch might be considered if you cannot tolerate NETA or LNG specifically, you have a documented allergy to patch adhesive components in the branded products, or cost is a genuine barrier after exhausting manufacturer coupons. Even then, using a separate oral micronized progesterone plus a branded estradiol-only patch may be preferable to a compounded combination patch, because oral progesterone has its own safety record and the estradiol patch (Climara, Vivelle-Dot) is FDA-approved.

Perimenopausal Women (Still Having Periods or Irregular Cycles)

This stage is more complex. Perimenopause is defined as the transition period leading to menopause, typically beginning in the mid-to-late 40s, marked by cycle irregularity and fluctuating FSH. You may still be ovulating sporadically. Combination HRT patches do not provide reliable contraception.

ACOG Practice Bulletin on menopause notes that perimenopausal women with vasomotor symptoms who still need contraception should consider hormonal contraception (such as a low-dose combined oral contraceptive or a hormonal IUD) that addresses both needs simultaneously, rather than HRT-dose patches that carry no contraceptive indication.

If you are perimenopausal, not at risk for pregnancy (confirmed non-fertile partner, surgical sterilization, or confirmed anovulation), and have significant vasomotor symptoms, a branded combination patch can be used. Your prescriber will typically assess cycle history and FSH before making this call.

Women With PCOS

Polycystic ovary syndrome deserves a specific note. Women with PCOS who reach perimenopause may have androgen excess as a baseline feature. Climara Pro's levonorgestrel is relatively androgenic compared to NETA or, especially, micronized progesterone. For PCOS-affected women starting menopausal HRT, CombiPatch (NETA) or a separate estradiol patch plus oral micronized progesterone may be preferable to Climara Pro to avoid compounding androgenic effects. No head-to-head trial specifically addresses PCOS women in the menopausal transition, which is an evidence gap worth naming.

Women With Prior Endometriosis or Fibroids

Endometriosis can persist or reactivate with unopposed estrogen even after menopause. Continuous combined therapy, which is what both branded patches provide, is generally preferred over sequential regimens for women with a history of endometriosis because the progestogen is given daily without a hormone-free interval. NETA has some direct anti-endometriotic properties in addition to its progestogenic effects. A review in the American Journal of Obstetrics and Gynecology supports continuous combined therapy for this group, though evidence specific to the transdermal route is thinner than for oral combinations.

Fibroids may grow in response to estrogen. Postmenopausal fibroid growth on HRT occurs in a subset of women, and monitoring with pelvic ultrasound is standard for women with known fibroids starting any estrogen-containing HRT.

Pregnancy and Lactation: What You Must Know

These patches are contraindicated in pregnancy. Estrogen-progestogen combinations at HRT doses are not indicated in pregnant women and animal data shows fetal risk with progestogen exposure in early pregnancy. If there is any possibility you could be pregnant, a pregnancy test must be performed before initiating therapy. Because perimenopausal women may still ovulate, this is a real clinical consideration, not a theoretical one.

Contraception requirement for perimenopausal women: HRT patches do not suppress ovulation reliably. ACOG and The Menopause Society both state that women who may still be fertile need dedicated contraception alongside HRT-dose preparations. Options include a hormonal IUD (which provides local endometrial progestogen and contraception, and could potentially allow you to use an estradiol-only patch for the systemic component), barrier methods, or sterilization confirmation.

Lactation: These patches are not used postpartum or during lactation. Postpartum estrogen can suppress milk supply, and NETA and LNG transfer into breast milk. Postpartum women with vasomotor symptoms (which can occur with postpartum estrogen withdrawal) are not candidates for menopausal HRT. If you are postpartum and experiencing hot flashes, the mechanism is different from menopause and HRT is not the appropriate treatment. Speak with your OB about postpartum hormonal management.

Drug interactions and contraception: If you are perimenopausal and using enzyme-inducing medications (rifampin, certain antiepileptics), patch hormone levels may be reduced, compounding the already unreliable contraceptive picture. Enzyme inducers are a reason to favor oral contraceptives with dose adjustment over a patch in this setting.

Compounded Patches: Where the Evidence Sits

The core argument for compounded patches is customization. A prescriber can specify a progestogen that neither branded patch contains (for example, progesterone itself, though skin penetration of progesterone is poor), a different estrogen dose, or an estrogen-progestogen ratio not available in branded options.

The argument against compounded combination patches, stated directly:

1. No endometrial biopsy data: No compounded transdermal combination product has completed a trial showing endometrial safety equivalent to the branded patches at 12 months. This is the fundamental safety question for any woman with a uterus.

2. No FDA potency verification: The FDA's 2020 report on compounded drug products found that a meaningful percentage of compounded preparations fail potency testing. For sex hormones, either too much or too little progestogen has clinical consequences.

3. Inconsistent release kinetics: A compounded patch formulated by one pharmacy will not have the same release profile as the same formulation from a different pharmacy, or even a different batch from the same pharmacy.

4. No pharmacovigilance database: Adverse events from compounded products are underreported and not captured in the same post-marketing surveillance systems as branded drugs. The FDA's MedWatch system captures reports for approved products systematically; compounded product adverse events are far less traceable.

The Menopause Society's 2022 position statement on compounded hormone therapy states that compounded hormones should not be recommended as a first-line or equivalent alternative to FDA-approved hormone therapy. This applies specifically to combination products, where the stakes of progestogen inadequacy are endometrial protection.

The Cost Reality

CombiPatch and Climara Pro carry list prices that can exceed $200 per month without insurance. Compounded patches are often significantly cheaper. This is a real barrier. Before moving to a compounded product for cost reasons alone, it is worth checking:

• Manufacturer patient assistance programs (Noven and Bayer both have programs for branded patches)
• GoodRx pricing for branded patches (can substantially reduce out-of-pocket cost at certain pharmacies)
• Whether a separate branded estradiol-only patch (Vivelle-Dot, Minivelle) plus oral micronized progesterone (Prometrium, which is also available as a generic) reaches a lower total cost while maintaining both FDA approval and endometrial safety data

Applying the Patch: Practical Details That Matter

Both branded patches should be applied to clean, dry skin on the lower abdomen or buttocks. Avoid the breasts. Rotate sites to reduce skin irritation. CombiPatch should be replaced every 3-4 days (twice weekly). Climara Pro is replaced once weekly.

If a patch falls off, reapply it or apply a new one and continue on the original schedule. Do not double-patch to make up for a missed application.

Skin reactions are more common with some branded patch formulations than others. A review in the journal Menopause found that adhesive skin reactions were among the most common reasons women switched or discontinued transdermal HRT. If you develop persistent erythema or pruritus under a patch, your prescriber can switch the branded product (the adhesive matrix differs between CombiPatch and Climara Pro) before moving to a compounded option.

Monitoring After You Start

Once you begin a combination patch, standard monitoring includes:

• Endometrial assessment if unexpected bleeding occurs after the first 6 months. Irregular bleeding in the first few months is common as the endometrium adjusts; persistent or late-onset bleeding needs evaluation.
• Annual blood pressure check (estrogen can modestly raise blood pressure in some women).
• Breast surveillance per your standard schedule. The combination of estrogen plus progestogen, particularly synthetic progestogens like NETA and LNG, is associated with a modestly higher breast cancer signal than estrogen alone. The WHI combined HRT arm demonstrated a hazard ratio of approximately 1.24 for invasive breast cancer with conjugated estrogens plus medroxyprogesterone acetate. The specific risk with transdermal NETA or LNG is less well-established, which is an acknowledged evidence gap.
• Symptom reassessment at 3 months, then annually, to confirm the dose remains appropriate.

The goal is to use the lowest effective dose for the shortest duration consistent with your individual treatment goals, per The Menopause Society's guidance.